Refine your results

to


Search

Dapagliflozin lowers all-cause mortality risk in type 2 diabetes

Show Citation

February 27, 2017

AUTHORS:

Toulis KA, Willis BH, Marshall T, Kumarendran B, Gokhale K, Ghosh S, Thomas GN, Cheng K, Narendran P, Hanif W, Nirantharakumar K.

CONTEXT:

Empagliflozin was found to decrease mortality in patients with type 2 diabetes (T2DM) and a prior cardiovascular (CVD) event. ...

Advertisement
Advertisement